NIH and NIGMS have policies to promote the successful entry of junior investigators into independent biomedical research careers. NIH classifies investigators who have not previously had a major NIH grant into two categories: new investigators (NIs) and early stage investigators (ESIs), a subset of NIs who are within 10 years of completing their terminal research degree or medical residency. The goal of these policies is to support R01-equivalent awards to both of these categories of investigators at success rates (the percentage of new Type 1 R01 applications that were funded) similar to those of established investigators (EIs) who submit new R01 applications.
Given that the NI and ESI policies have been in effect for some time, we wanted to update and extend an analysis of success rates by investigator status performed in 2010 to see if NIGMS has been able to meet these objectives. While we found that the success rates for all NIs were comparable to or greater than that of EIs, our new analysis also revealed that the subset of NIs who completed their terminal research degree at least 10 years ago (non-ES NIs) had consistently lower success rates in obtaining R01s relative to both ESIs and EIs.
We focused our analysis on NIGMS Type 1 R01 applications for Fiscal Years 2011-2014. Figure 1a shows the success rates for EIs and NIs. During the time period analyzed, success rates for both EIs and NIs were comparable. However, when the NIs are separated into ESIs and non-ES NIs, the data show a more nuanced result (Figure 1b). ESIs consistently had higher success rates than either EIs or non-ES NIs when applying for new R01s.
Continue reading “Analysis of NIGMS Funding Rates for Early Stage Investigators and Non-Early Stage New Investigators”
NIGMS Staff Participating in the February 8 Webinar
Jon Lorsch, Director, NIGMS
Alison Gammie, Director, Division of Training, Workforce Development, and Diversity
Shiva Singh, Chief, Undergraduate and Predoctoral Training Branch, Division of Training, Workforce Development, and Diversity
Kris Willis, Program Director, Division of Genetics and Developmental Biology
Lisa Moeller, Grants Management Officer
UPDATE: To join this meeting, visit Webinar on Administrative Supplements to T32 Grants, PA-16-060 and click “OK.” The site is compatible with mobile devices. For a voice-only presentation, call 1-888-469-2151 from anywhere in the United States or Canada and enter the access code 8911526.
We’ll field your questions about the recently announced Availability of Administrative Supplements to NIGMS Predoctoral Training Grants during a webinar on Monday, Feb. 8, from 3:15-4:15 p.m. EST. Details about how to access the webinar online will be available soon. You can send questions to me ahead of time.
Since announcing this funding opportunity, we’ve received many inquiries. The following points address most of the common questions:
- The supplement is designed to provide support for the development and implementation of curricular activities aimed at providing graduate students with a strong foundation in research design and methods in areas related to conducting reproducible and rigorous research.
- To be eligible, your training grant must be active through at least June 30, 2018. Thus, training grants that might have received outstanding priority scores and are expected to be renewed effective July 1, 2016, are NOT eligible.
Continue reading “Webinar on Training Grant Supplements”
This blog is one way that we reach out to the scientific community with information about research and research training policies, funding opportunities, analyses, resources, meetings and other useful news. It’s also a key way in which we get your input on our activities and plans.
When I looked back at some recent posts, I was struck by how many of them are relevant to the graduate students and postdocs in your labs. For example, the post describing our plans to modernize graduate education is a must-read for graduate students, whose ideas and perspective will further inform our efforts. The post on talking to NIH staff about your application and grant provides essential information for postdocs who will soon be independent investigators.
Please encourage your students and postdocs to subscribe to the Feedback Loop as well as to send us their suggestions for topics to cover in future posts.
NIH has launched a major new initiative called the Environmental Influences on Child Health Outcomes (ECHO) program to investigate environmental exposures on child health and development. An important component of the program will be the IDeA States Pediatric Clinical Trials Network (ISPCTN), which the Eunice Kennedy Shriver National Institute of Child Health and Human Development is leading in collaboration with us.
The ISPCTN will give medically underserved and rural populations access to state-of-the-art pediatric clinical trials. The network’s clinical trials sites, which will be located in states eligible for funding through our Institutional Development Award (IDeA) program, will receive support for the development of appropriate research infrastructure as well as supervised professional development in all aspects of clinical trials research and implementation. We expect the ISPCTN to help strengthen pediatric research opportunities and capacity in IDeA states, which historically have not received extensive NIH funding.
If you’re in an IDeA-eligible state (including Puerto Rico), we encourage you to apply to either or both of the ISPCTN FOAs:
Applications proposing studies on all pediatric diseases and conditions will be considered, but priority will be given to those on the focus areas and core elements of the ECHO program, which include upper and lower airway disease; obesity; pre-, peri-, and postnatal outcomes; and neurodevelopment. The application deadline for both announcements is April 15, 2016, with optional letters of intent due by March 15, 2016.
For more information about the ECHO program and its various FOAs, you can participate in webinars scheduled for January 14, 2016, and February 1, 2016, or contact one of us (email@example.com, firstname.lastname@example.org).